Six Questions For Novartis CEO Narasimhan
Novartis CEO Vas Narasimhan outlines how the company is progressing data science and digital transformation across operations, including plans to use predictive analytics to forecast production supply chain runs. The Swiss firm is also monitoring the evolving coronavirus situation closely but has safety stocks for its key products and innovative medicine portfolio and is "okay" for now.
You may also be interested in...
Novartis India chief outlines how the company is navigating the challenging business environment amid the coronavirus pandemic, including for its for-profit social business. Digital solutions are a key part of these efforts and the executive offers advice for those struggling to balance the work-life mix in these testing times.
Parexel executives tell Scrip about the company’s efforts in tandem with sponsors to navigate the challenging clinical research environment amid COVID-19. A renewed interest for decentralized trials or hybrid approaches and the use of remote monitoring and telehealth visits to keep studies moving are some of the key initiatives.
Partnership includes provision for fast-tracked uptake of inclisiran in England, if NICE finds it cost effective.